PARP1 and myelodysplastic syndrome: (39) conducted a meta-analysis of 28 randomized controlled trials (RCTs) of PARP inhibitors published between March 2012 and April 2020 to assess the occurrence of MDS/AML associated with PARPi and found that all cases of MDS/AML were observed in ovarian cancer patients.